Myriad Genetics Reports $365.9M Net Loss and $319.4M Impairment in 2025 Annual Report

summarizeSummary

Myriad Genetics reported a $365.9 million net loss for 2025, including $319.4 million in goodwill and intangible asset impairments, alongside a 2% revenue decline. The company secured new debt and saw positive operating cash flow, while also undergoing significant leadership changes and advancing product development.

check_boxKey Events

• Significant Net Loss

  Reported a net loss of $365.9 million for the fiscal year ended December 31, 2025, a substantial increase from $127.3 million in 2024.

• Major Impairment Charges

  Recognized $319.4 million in goodwill and intangible asset impairment charges, primarily affecting the Mental Health ($91.2M goodwill, $71.8M intangible) and Women's Health ($143.5M goodwill) reporting units.

• Revenue Decline & Segment Weakness

  Total revenue decreased 2% year-over-year to $824.5 million, with Mental Health revenue specifically declining 15% due to changes in UnitedHealthcare coverage.

• Improved Operating Cash Flow & New Debt Facility

  Achieved positive cash flow from operations of $1.8 million in 2025 (vs. -$8.7 million in 2024) and secured a new $125 million secured term loan facility with an additional $75 million available, used in part to repay $60.2 million of previous debt.

auto_awesomeAnalysis

The 2025 Annual Report, following a preliminary 8-K on February 23, 2026, reveals a substantial net loss of $365.9 million, primarily driven by significant goodwill and intangible asset impairment charges totaling $319.4 million. This impairment, representing a large portion of the company's market capitalization, indicates a material revaluation of prior acquisitions and assets, particularly within the Mental Health and Women's Health segments. While total revenue saw a modest 2% decline, the 15% drop in Mental Health revenue due to changes in UnitedHealthcare coverage is a notable concern. On a positive note, the company achieved positive cash flow from operations of $1.8 million, a significant improvement from the prior year's negative cash flow, and secured a new $125 million term loan facility to enhance liquidity. The report also highlights ongoing strategic initiatives, including product expansions, new collaborations, and a major C-suite leadership transition, signaling efforts to navigate challenges and drive future growth. Investors should closely monitor the impact of the impairment on future profitability and the effectiveness of the new management team's strategic plan.